FDA accepts Incyte’s NDA for priority review of pemigatinib to treat cholangiocarcinoma

This article was originally published here

The NDA has been accepted for the priority review of selective fibroblast growth factor receptor (FGFR) inhibitor pemigatinib to treat patients with previously treated, locally advanced or metastatic

The post FDA accepts Incyte’s NDA for priority review of pemigatinib to treat cholangiocarcinoma appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply